Proof of concept for claudin-targeted drug development

Annals of the New York Academy of Sciences

Volumn 1258, Issue 1, 2012, Pages 65-70

  Suzuki, Hidehiko ^a   Kondoh, Masuo ^a   Takahashi, Azusa ^a   Yagi, Kiyohito ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

Cancer targeting; Claudin; Clostridium perfringens enterotoxin; Mucosal absorption; Vaccination

Indexed keywords

C TERMINAL FRAGMENT OF CLOSTRIDIUM PERFRINGENS ENTEROTOXIN; CLAUDIN; ENTEROTOXIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CLOSTRIDIUM PERFRINGENS; CLOSTRIDIUM PERFRINGENS INFECTION; DRUG ABSORPTION; EPITHELIUM CELL; GENE OVEREXPRESSION; HUMAN; MUCOSAL IMMUNITY; NEOPLASM; NONHUMAN; TIGHT JUNCTION;

CLOSTRIDIUM PERFRINGENS; TETRA;

EID: 84862838191     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2012.06503.x     Document Type: Article

References (43)

1. Powell, D.W. 1981. Barrier function of epithelia. Am. J. Physiol. 241: G275-G288.
2. Wodarz, A. & I. Nathke 2007. Cell polarity in development and cancer. Nat. Cell Biol. 9: 1016-1024.
3. Schneeberger, E.E. & R.D. Lynch 2004. The tight junction: a multifunctional complex. Am. J. Physiol. 286: C1213-C1228.
4. Kondoh, M., A. Masuyama, A. Takahashi, et al 2005. A novel strategy for the enhancement of drug absorption using a claudin modulator. Mol. Pharmacol. 67: 749-756.
5. Kominsky, S.L., B. Tyler, J. Sosnowski, et al 2007. Clostridium perfringens enterotoxin as a novel-targeted therapeutic for brain metastasis. Cancer Res. 67: 7977-7982.
6. Morin, P.J. 2005. Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer Res. 65: 9603-9606.
7. Tamagawa, H., I. Takahashi, M. Furuse, et al 2003. Characteristics of claudin expression in follicle-associated epithelium of Peyer's patches: preferential localization of claudin-4 at the apex of the dome region. Lab. Invest. 83: 1045-1053.
8. Morita, K., M. Furuse, K. Fujimoto, et al 1999. Claudin multigene family encoding four-transmembrane domain protein components of tight junction strands. Proc. Natl. Acad. Sci. USA 96: 511-516.
9. Sonoda, N., M. Furuse, H. Sasaki, et al 1999. Clostridium perfringens enterotoxin fragment removes specific claudins from tight junction strands: evidence for direct involvement of claudins in tight junction barrier. J. Cell Biol. 147: 195-204.
10. McClane, B.A. 1992. Clostridium perfringens enterotoxin: structure, action and detection. J. Food Saf. 12: 237-252.
11. Windsor, E. & G.E. Cronheim 1961. Gastro-intestinal absorption of heparin and synthetic heparinoids. Nature. 190: 263-264.
12. Aungst, B.J. 2000. Intestinal permeation enhancers. J. Pharm. Sci. 89: 429-442.
13. Van Itallie, C.M. & J.M. Anderson 2006. Claudins and epithelial paracellular transport. Annu. Rev. Physiol. 68: 403-429.
14. Furuse, M., M. Hata, K. Furuse, et al 2002. Claudin-based tight junctions are crucial for the mammalian epidermal barrier: a lesson from claudin-1-deficient mice. J. Cell Biol. 156: 1099-1111.
15. Nitta, T., M. Hata, S. Gotoh, et al 2003. Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. J. Cell Biol. 161: 653-660.
16. Furuse, M., H. Sasaki, K. Fujimoto, et al 1998. A single gene product, claudin-1 or -2, reconstitutes tight junction strands and recruits occludin in fibroblasts. J. Cell Biol. 143: 391-401.
17. Uchida, H., M. Kondoh, T. Hanada, et al 2010. A claudin-4 modulator enhances the mucosal absorption of a biologically active peptide. Biochem. Pharmacol. 79: 1437-1444.
18. Furuse, M. & S. Tsukita 2006. Claudins in occluding junctions of humans and flies. Trends Cell Biol. 16: 181-188.
19. Loisel, T.P., H. Ansanay, S. St-Onge, et al 1997. Recovery of homogeneous and functional beta 2-adrenergic receptors from extracellular baculovirus particles. Nat. Biotechnol. 15: 1300-1304.
20. Strehlow, D., S. Jodo & S.T. Ju 2000. Retroviral membrane display of apoptotic effector molecules. Proc. Natl. Acad. Sci. USA 97: 4209-4214.
21. Hayashi, I., Y. Urano, R. Fukuda, et al 2004. Selective reconstitution and recovery of functional gamma-secretase complex on budded baculovirus particles. J. Biol. Chem. 279: 38040-38046.
22. Masuda, K., H. Itoh, T. Sakihama, et al 2003. A combinatorial G protein-coupled receptor reconstitution system on budded baculovirus. Evidence for Galpha and Galphao coupling to a human leukotriene B4 receptor. J. Biol. Chem. 278: 24552-24562.
23. Kakutani, H., A. Takahashi, M. Kondoh, et al 2011. A novel screening system for claudin binder using baculoviral display. PLoS One. 6: e16611.
24. Takahashi, A., E. Komiya, H. Kakutani, et al 2008. Domain mapping of a claudin-4 modulator, the C-terminal region of C-terminal fragment of Clostridium perfringens enterotoxin, by site-directed mutagenesis. Biochem. Pharmacol. 75: 1639-1648.
25. Takahashi, A., M. Kondoh, A. Masuyama, et al 2005. Role of C-terminal regions of the C-terminal fragment of Clostridium perfringens enterotoxin in its interaction with claudin-4. J. Control. Release. 108: 56-62.
26. Kominsky, S.L. 2006. Claudins: emerging targets for cancer therapy. Expert Rev. Mol. Med. 8: 1-11.
27. Agarwal, R., T. D'Souza & P.J. Morin 2005. Claudin-3 and claudin-4 expression in ovarian epithelial cells enhances invasion and is associated with increased matrix metalloproteinase-2 activity. Cancer Res. 65: 7378-7385.
28. Dhawan, P., A.B. Singh, N.G. Deane, et al 2005. Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer. J. Clin. Invest. 115: 1765-1776.
29. Michl, P., M. Buchholz, M. Rolke, et al 2001. Claudin-4: a new target for pancreatic cancer treatment using Clostridium perfringens enterotoxin. Gastroenterology 121: 678-684.
30. Ebihara, C., M. Kondoh, N. Hasuike, et al 2006. Preparation of a claudin-targeting molecule using a C-terminal fragment of Clostridium perfringens enterotoxin. J. Pharmacol. Exp. Ther. 316: 255-260.
31. Saeki, R., M. Kondoh, H. Kakutani, et al 2009. A novel tumor-targeted therapy using a claudin-4-targeting molecule. Mol. Pharmacol. 76: 918-926.
32. Saeki, R., M. Kondoh, H. Kakutani, et al 2010. A claudin-targeting molecule as an inhibitor of tumor metastasis. J. Pharmacol. Exp. Ther. 334: 576-582.
33. Meunier, V., M. Bourrie, Y. Berger, et al 1995. The human intestinal epithelial cell line Caco-2; pharmacological and pharmacokinetic applications. Cell Biol. Toxicol. 11: 187-194.
34. Boyaka, P.N., M. Marinaro, J.L. Vancott, et al 1999. Strategies for mucosal vaccine development. Am. J. Trop. Med. Hyg. 60: 35-45.
35. Cardenas-Freytag, L., E. Cheng & A. Mirza 1999. New approaches to mucosal immunization. Adv. Exp. Med. Biol. 473: 319-337.
36. Michels, K.B. & H. zur Hausen 2009. HPV vaccine for all. Lancet. 374: 268-270.
37. Kiyono, H. & S. Fukuyama 2004. NALT- versus Peyer's-patch-mediated mucosal immunity. Nat. Rev. Immunol. 4: 699-710.
38. Kunisawa, J., S. Fukuyama & H. Kiyono 2005. Mucosa-associated lymphoid tissues in the aerodigestive tract: their shared and divergent traits and their importance to the orchestration of the mucosal immune system. Curr. Mol. Med. 5: 557-572.
39. Kakutani, H., M. Kondoh, M. Fukasaka, et al 2010. Mucosal vaccination using claudin-4-targeting. Biomaterials. 31: 5463-5471.
40. Suzuki, H., M. Kondoh, X. Li, et al 2011. A toxicological evaluation of a claudin modulator, the C-terminal fragment of Clostridium perfringens enterotoxin, in mice. Pharmazie. 66: 543-546.
41. Fofana, I., S.E. Krieger, F. Grunert, et al 2010. Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. Gastroenterology. 139: 953-964.
42. Suzuki, M., M. Kato-Nakano, S. Kawamoto, et al 2009. Therapeutic antitumor efficacy of monoclonal antibody against Claudin-4 for pancreatic and ovarian cancers. Cancer Sci. 100: 1623-1630.
43. Kato-Nakano, M., M. Suzuki, S. Kawamoto, et al 2010. Characterization and evaluation of the antitumour activity of a dual-targeting monoclonal antibody against claudin-3 and claudin-4. Anticancer Res. 30: 4555-4562.